AZ's Brilinta Takes Next Step, Gains FDA Approval For Extended Use
This article was originally published in Scrip
Executive Summary
The US FDA has approved AstraZeneca PLC's oral antiplatelet treatment, Brilinta (ticagrelor), in a new indication, allowing the product to be used as a longer term therapy for patients with acute coronary syndrome (ACS).
You may also be interested in...
AstraZeneca Groomed Paul Hudson For His New Role … At Novartis
Ten years at AstraZeneca PLC have prepared US President and Executive Vice President of North America Paul Hudson for his next C-suite job, but unfortunately for his current employer that gig is with a major competitor – Novartis AG.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.